Related references
Note: Only part of the references are listed.appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies)
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2017)
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
Heidi D. Finnes et al.
LEUKEMIA & LYMPHOMA (2017)
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)
Tait D. Shanafelt et al.
LEUKEMIA & LYMPHOMA (2017)
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
Jennifer R. Brown et al.
HAEMATOLOGICA (2017)
14-ICML Satellite symposia programs and abstracts (updated on May 21 2017)
HEMATOLOGICAL ONCOLOGY (2017)
NCCN Guidelines® Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines
William G. Wierda et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies
J. J. Shatzel et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib
Khai Li Chai et al.
LEUKEMIA & LYMPHOMA (2017)
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
Jennifer R. Brown et al.
HAEMATOLOGICA (2017)
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
Benjamin Arthurs et al.
RESPIRATORY MEDICINE CASE REPORTS (2017)
An update for Richter syndrome - new directions and developments
Toby A. Eyre et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Ibrutinib-associated skin toxicity: a case of maculopapular rash in a 79-year old Caucasian male patient with relapsed Waldenstroms macroglobulinemia and review of the literature
Anders Bisgaard Jensen et al.
DERMATOLOGY REPORTS (2017)
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib
Jeffrey A. Jones et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Paul M. Barr et al.
BLOOD (2017)
Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis
Francois Caron et al.
BLOOD ADVANCES (2017)
How I manage ibrutinib-refractory chronic lymphocytic leukemia
Jennifer A. Woyach
BLOOD (2017)
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E. Ahn et al.
BLOOD (2017)
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia
K. A. Rogers et al.
LEUKEMIA (2016)
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib
Inhye E. Ahn et al.
BLOOD (2016)
Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders
Stephen P. Mulligan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling
L. de Zwart et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2016)
Ibrutinib in the real world patient: many lights and some shades
Paolo Ghia et al.
HAEMATOLOGICA (2016)
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Maria Winqvist et al.
HAEMATOLOGICA (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
Candida Vitale et al.
HAEMATOLOGICA (2016)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Martin Dreyling et al.
LANCET (2016)
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
Michael L. Wang et al.
LANCET ONCOLOGY (2016)
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Susan O'Brien et al.
LANCET ONCOLOGY (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Ibrutinib in the real world patient: many lights and some shades
Paolo Ghia et al.
HAEMATOLOGICA (2016)
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Maria Winqvist et al.
HAEMATOLOGICA (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
Candida Vitale et al.
HAEMATOLOGICA (2016)
BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
Lorenzo Falchi et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2016)
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib
Clare Sun et al.
BLOOD (2015)
Racial differences in three major NHL subtypes: Descriptive epidemiology
Yang Li et al.
CANCER EPIDEMIOLOGY (2015)
Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century
Dianne Pulte et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia
Gabriel Mannis et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
S. Kamel et al.
LEUKEMIA (2015)
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Marie Levade et al.
BLOOD (2014)
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
Jennifer A. Woyach et al.
BLOOD (2014)
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension
Giuseppe Mancia et al.
BLOOD PRESSURE (2014)
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
S. E. M. Herman et al.
LEUKEMIA (2014)
The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era
Chadi Nabhan et al.
LEUKEMIA & LYMPHOMA (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib: a paradigm shift in management of CLL
Talha Badar et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
Guideline on the management of bleeding in patients on antithrombotic agents
Mike Makris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Infectious Complications in Patients With Chronic Lymphocytic Leukemia: Pathogenesis, Spectrum of Infection, and Approaches to Prophylaxis
Vicki A. Morrison
CLINICAL LYMPHOMA & MYELOMA (2009)
Share Paper
